6 Undervalued Healthcare Facilities & Services Stocks for Tuesday, April 02

By AAII Staff
April 02, 2024
Diamond graphic indicating best value stocks in their industry
Featured Tickers:
CVS NVOS OGI SEM UHS

Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 6 stocks made the list for top value stocks in the Healthcare Facilities & Services industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.

Why Focus on Undervalued Healthcare Facilities & Services Stocks?

Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.

AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

What Goes Into AAII’s Value Grade?

Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.

Click the button below to learn more about A+ Investor and subscribe today.

Learn More About A+ Investor

6 Undervalued Healthcare Facilities & Services Stocks

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 6 undervalued stocks in the Healthcare Facilities & Services industry for Tuesday, April 02, 2024. Let’s take a closer look at their individual scores to see how they measure up against each other and the Healthcare Facilities & Services industry median.

Company Ticker Price/Sales Price/Earnings EV/EBITDA Shareholder Yield Price/Book Value Price/Free Cash Flow Value Grade
CVS Health Corp CVS 0.29 12.3 8.0 4.9% 1.34 14.1 A
Novo Integrated Sciences Inc NVOS 0.62 na na (394.1%) 0.34 na B
OrganiGram Holdings Inc OGI 1.08 na na (3.6%) 0.65 na B
Psychemedics Corp. PMD 0.72 na na 7.5% 2.45 na B
Select Medical Holdings Corp SEM 0.55 15.7 8.9 0.6% 2.86 12.8 B
Universal Health Services, Inc. UHS 0.83 17.1 8.7 5.2% 1.93 26.1 B

The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.

The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)

Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).

As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.

CVS Health Corp’s Value Grade

Value Grade:

Metric Score CVS Industry Median
Price/Sales 11 0.29 1.14
Price/Earnings 32 12.3 25.1
EV/EBITDA 36 8.0 13.1
Shareholder Yield 18 4.9% (1.7%)
Price/Book Value 40 1.34 2.33
Price/Free Cash Flow 40 14.1 23.1

CVS Health Corporation is a health solutions company. The Company operates in four segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. Its Health Care Benefits segment offer a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare supplement plans, and Medicaid health care management services. Its Health Services segment provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services, including pharmacy patient care programs, diagnostic testing and vaccination administration.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

CVS Health Corp has a Value Score of 84, which is considered to be undervalued.

When you look at CVS Health Corp’s price-to-sales ratio at 0.29 compared to the industry median at 1.14, this company has a lower price relative to revenue compared to its peers. This could make CVS Health Corp’s stock more attractive for value investors.

CVS Health Corp’s price-earnings ratio is 12.30 compared to the industry median at 25.11. This means it has a lower share price relative to earnings compared to its peers. This could make CVS Health Corp more attractive for value investors.

Now, let’s assess CVS Health Corp’s EV/EBITDA ratio, also known as enterprise multiple. At 8.0, when compared to the industry median of 13.1, the company may be considered undervalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.

Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. CVS Health Corp’s shareholder yield is higher than its industry median ratio of (1.65%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.

As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. CVS Health Corp’s price-to-book ratio is lower than its industry median ratio of 2.33. This could make CVS Health Corp more attractive to investors looking for a new addition to their portfolio.

Lastly, let’s take a look at CVS Health Corp’s price-to-free-cash-flow ratio (P/FCF), which can indicate a company’s market value relative to its operating cash flow. CVS Health Corp’s price-to-free-cash-flow ratio is lower than its industry median ratio of 23.05. This could make CVS Health Corp more attractive because the lower P/FCF ratio indicates that CVS Health Corp is undervalued. The P/FCF ratio metric can also be viewed over a long-term time frame to see if the company's cash flow to share price value is generally improving or worsening.

Novo Integrated Sciences Inc’s Value Grade

Value Grade:

Metric Score NVOS Industry Median
Price/Sales 22 0.62 1.14
Price/Earnings na na 25.1
EV/EBITDA na na 13.1
Shareholder Yield 99 (394.1%) (1.7%)
Price/Book Value 6 0.34 2.33
Price/Free Cash Flow na na 23.1

Novo Integrated Sciences, Inc. is a parent company to its subsidiaries. The Company owns Canadian and United States subsidiaries that provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutic, diagnostic solutions, personalized product offerings, and rehabilitative science. The Company operates through two segments: Healthcare Services and Product Sales. Its specialized multidisciplinary primary healthcare services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, dietician and others. Its subsidiaries include Novo Healthnet Limited, Novomerica Health Group, Inc., PRO-DIP, LLC and others.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Novo Integrated Sciences Inc has a Value Score of 61, which is considered to be undervalued.

Novo Integrated Sciences Inc’s price-to-book ratio is higher than its peers. This could make Novo Integrated Sciences Inc less attractive for value investors when compared to the industry median at 2.33.

You can read more about Novo Integrated Sciences Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

OrganiGram Holdings Inc’s Value Grade

Value Grade:

Metric Score OGI Industry Median
Price/Sales 35 1.08 1.14
Price/Earnings na na 25.1
EV/EBITDA na na 13.1
Shareholder Yield 71 (3.6%) (1.7%)
Price/Book Value 14 0.65 2.33
Price/Free Cash Flow na na 23.1

Organigram Holdings Inc. operates through its subsidiaries. The Company’s major wholly owned subsidiaries include Organigram Inc., 10870277 Canada Inc., The Edibles and Infusions Corporation (EIC), and Laurentian Organic Inc. (Laurentian). Organigram Inc. is a licensed producer (LP) of cannabis, cannabis-derived products and cannabis infused edibles in Canada. It is focused on producing cannabis for patients and adult recreational consumers, as well as developing international business partnerships. It has also developed and owns a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. It operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. 10870277 Canada Inc. is a special purpose holding company for the Company. EIC is a cannabis processor of confectionary goods.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

OrganiGram Holdings Inc has a Value Score of 65, which is considered to be undervalued.

OrganiGram Holdings Inc’s price-to-book ratio is higher than its peers. This could make OrganiGram Holdings Inc less attractive for value investors when compared to the industry median at 2.33.

You can read more about OrganiGram Holdings Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Psychemedics Corp.’s Value Grade

Value Grade:

Metric Score PMD Industry Median
Price/Sales 25 0.72 1.14
Price/Earnings na na 25.1
EV/EBITDA na na 13.1
Shareholder Yield 12 7.5% (1.7%)
Price/Book Value 62 2.45 2.33
Price/Free Cash Flow na na 23.1

Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Psychemedics Corp. has a Value Score of 78, which is considered to be undervalued.

Psychemedics Corp.’s price-to-book ratio is lower than its peers. This could make Psychemedics Corp. more attractive for value investors when compared to the industry median at 2.33.

You can read more about Psychemedics Corp.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Select Medical Holdings Corp’s Value Grade

Value Grade:

Metric Score SEM Industry Median
Price/Sales 20 0.55 1.14
Price/Earnings 43 15.7 25.1
EV/EBITDA 42 8.9 13.1
Shareholder Yield 40 0.6% (1.7%)
Price/Book Value 68 2.86 2.33
Price/Free Cash Flow 37 12.8 23.1

Select Medical Holdings Corporation operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers. Its segments include critical illness recovery hospital, rehabilitation hospital, outpatient rehabilitation, and Concentra. The critical illness recovery hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. Its Concentra segment consists of occupational health centers that provide workers’ compensation injury care, physical therapy, and consumer health services and onsite clinics located at employer worksites that deliver occupational health services.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Select Medical Holdings Corp has a Value Score of 62, which is considered to be undervalued.

Select Medical Holdings Corp’s price-earnings ratio is 15.7 compared to the industry median at 25.1. This means that it has a lower price relative to its earnings compared to its peers. This makes Select Medical Holdings Corp more attractive for value investors.

Select Medical Holdings Corp’s price-to-book ratio is lower than its peers. This could make Select Medical Holdings Corp more attractive for value investors when compared to the industry median at 2.33.

You can read more about Select Medical Holdings Corp’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Universal Health Services, Inc.’s Value Grade

Value Grade:

Metric Score UHS Industry Median
Price/Sales 28 0.83 1.14
Price/Earnings 46 17.1 25.1
EV/EBITDA 41 8.7 13.1
Shareholder Yield 17 5.2% (1.7%)
Price/Book Value 54 1.93 2.33
Price/Free Cash Flow 63 26.1 23.1

Universal Health Services, Inc. is a holding company. It operates through its subsidiaries, including its management company. It is engaged in owning and operating acute care hospitals and outpatient facilities, and behavioral healthcare facilities. Its segments include acute care hospital services, behavioral health care services, and Other. It owns and operates approximately 360 inpatient facilities and 48 outpatient and other facilities located in 39 states, Washington, D.C., the United Kingdom, and Puerto Rico. It provides services, which include general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral health services. It also provides capital resources, as well as a variety of management services to its facilities, including information services, finance and control systems, facilities planning, physician recruitment services, and public relations.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Universal Health Services, Inc. has a Value Score of 63, which is considered to be undervalued.

Universal Health Services, Inc.’s price-earnings ratio is 17.1 compared to the industry median at 25.1. This means that it has a lower price relative to its earnings compared to its peers. This makes Universal Health Services, Inc. more attractive for value investors.

Universal Health Services, Inc.’s price-to-book ratio is higher than its peers. This could make Universal Health Services, Inc. less attractive for value investors when compared to the industry median at 2.33.

You can read more about Universal Health Services, Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Learn More About A+ Investor

Other Healthcare Facilities & Services Stock Grades

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.

Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Healthcare Facilities & Services stocks as well as other industrys.

Choosing Which of the 6 Best Healthcare Facilities & Services Stocks Is Right for You

Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.

  • CVS Health Corp stock has a Value Grade of A.
  • Novo Integrated Sciences Inc stock has a Value Grade of B.
  • OrganiGram Holdings Inc stock has a Value Grade of B.
  • Psychemedics Corp. stock has a Value Grade of B.
  • Select Medical Holdings Corp stock has a Value Grade of B.
  • Universal Health Services, Inc. stock has a Value Grade of B.

Now that you have a bit more background about each of the 6 undervalued stocks in the Healthcare Facilities & Services industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.

We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.

A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

Learn More About A+ Investor

Additional Resources About Healthcare Facilities & Services Stocks

Want to learn more about Healthcare Facilities & Services stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.



Find New Stock Opportunities With Included With AAII Platinum
O'Shaughnessy Tiny Titans
Screen:
23.7%
Annual Gain Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.